Skip to content

Nasus Pharma Ltd

NSRX

CIK 0002029039

← back to feed
Revenue (TTM)
$1.24B
FY Dec 2025
Net Income (TTM)
−$5.86M
−282.2% YoY FY Dec 2025
EPS Diluted (TTM)
−$0.72
−227.3% YoY FY Dec 2025
Gross Margin
—
FY Dec 2025
Operating Margin
-0.4%
FY Dec 2025
Net Margin
-0.5%
FY Dec 2025
Free Cash Flow (TTM)
−$4.93M
FY Dec 2025
Cash
$1.24M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
9.02M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings